JNJ

164.66

-1.58%↓

NVS

113.6

-2.65%↓

ABT

126.18

-1.94%↓

TMO

467.7

-2.01%↓

ISRG

481.22

-3.79%↓

JNJ

164.66

-1.58%↓

NVS

113.6

-2.65%↓

ABT

126.18

-1.94%↓

TMO

467.7

-2.01%↓

ISRG

481.22

-3.79%↓

JNJ

164.66

-1.58%↓

NVS

113.6

-2.65%↓

ABT

126.18

-1.94%↓

TMO

467.7

-2.01%↓

ISRG

481.22

-3.79%↓

JNJ

164.66

-1.58%↓

NVS

113.6

-2.65%↓

ABT

126.18

-1.94%↓

TMO

467.7

-2.01%↓

ISRG

481.22

-3.79%↓

JNJ

164.66

-1.58%↓

NVS

113.6

-2.65%↓

ABT

126.18

-1.94%↓

TMO

467.7

-2.01%↓

ISRG

481.22

-3.79%↓

Search

Novo Nordisk A-S

Closed

SectorHealthcare

47.02 -6.07

Overview

Share price change

24h

Current

Min

46.9

Max

50.07

Key metrics

By Trading Economics

Income

804M

29B

Sales

-7.6B

78B

P/E

Sector Avg

18.649

40.048

EPS

6.53

Dividend yield

2.34

Profit margin

37.182

Employees

77,406

EBITDA

5.9B

46B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+45.91% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.34%

2.45%

Market Stats

By TradingEconomics

Market Cap

50B

316B

Previous open

53.09

Previous close

47.02

News Sentiment

By Acuity

57%

43%

315 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Novo Nordisk A-S Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2025, 12:41 UTC

Earnings

Novo Nordisk Shares Plummet on Guidance Cut as Wegovy Knockoffs Hurt Sales -- 2nd Update

29 Jul 2025, 11:36 UTC

Earnings

Novo Nordisk Cuts Guidance as Copycat Versions of Wegovy Hurt Results

30 Jul 2025, 11:10 UTC

Market Talk
Earnings

Novo Nordisk Suffering From Self-Inflicted Wounds -- Market Talk

30 Jul 2025, 10:57 UTC

Market Talk

Novo Nordisk's New CEO Might Need to Change U.S. Strategy -- Market Talk

30 Jul 2025, 10:48 UTC

Market Talk
Earnings

Novo Nordisk's New CEO Faces Issues With No Easy Fix -- Market Talk

30 Jul 2025, 10:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Stock Markets Beware Summer Scares. What -2-

30 Jul 2025, 10:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Stock Markets Beware Summer Scares. What Microsoft Must Learn From Novo's $75 Billion Crash. -- Barrons.com

30 Jul 2025, 10:38 UTC

Market Talk

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

30 Jul 2025, 10:26 UTC

Earnings

Global Earnings in Focus Wednesday: HSBC, UBS, Porsche, Hermès -- WSJ

29 Jul 2025, 17:05 UTC

Earnings

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 Jul 2025, 16:55 UTC

Earnings

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 Jul 2025, 13:35 UTC

Earnings

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29 Jul 2025, 11:39 UTC

Earnings

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

29 Jul 2025, 11:11 UTC

Earnings

Novo Nordisk Shares Fall Over 15% After Guidance Cut

29 Jul 2025, 11:09 UTC

Earnings

Novo Nordisk: Sales Outlook Reflects Persistent Use of Compounded GLP-1s, Slower Mkt Expansion, Competition

29 Jul 2025, 11:08 UTC

Earnings

Novo Nordisk: Lowered Sales Outlook Driven by Lower Growth Views for Wegovy, Ozempic in U.S.

29 Jul 2025, 11:08 UTC

Earnings

Novo Nordisk Had Seen 2025 Sales Growth at 13%-21%, Op Profit Growth at 16%-24%

29 Jul 2025, 11:07 UTC

Earnings

Novo Nordisk Cuts 2025 Sales and Op Profit Guidance

29 Jul 2025, 11:06 UTC

Earnings

Novo Nordisk 1H Sales Increased by 18% and Operating Profit Increased by 29%

29 Jul 2025, 11:06 UTC

Earnings

Novo Nordisk Now Sees 2025 Sales Growth at 8%-14%, Op Profit Growth at 10%-16%

29 Jul 2025, 11:05 UTC

Earnings

Novo Nordisk Cuts Sales and Operating Profit Outlook for 2025

15 Jul 2025, 12:38 UTC

Market Talk

Novo Nordisk Faces Several Questions on Wegovy -- Market Talk

9 Jul 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 Jul 2025, 09:17 UTC

Hot Stocks

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

24 Jun 2025, 10:26 UTC

Market Talk

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

23 Jun 2025, 13:09 UTC

Market Talk

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

20 Jun 2025, 13:31 UTC

Acquisitions, Mergers, Takeovers

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

13 Jun 2025, 11:39 UTC

Market Talk

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

13 Jun 2025, 10:04 UTC

Market Talk

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

11 Jun 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

Peer Comparison

Price change

Novo Nordisk A-S Forecast

Price Target

By TipRanks

45.91% upside

12 Months Forecast

Average 73 USD  45.91%

High 90 USD

Low 55 USD

Based on 5 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

62.63 / 69.23Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

315 / 375 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.